Arthritis Patents (Class 514/825)
-
Patent number: 7534430Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: September 28, 2006Date of Patent: May 19, 2009Assignee: Genetics Institute, LLCInventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 7517886Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.Type: GrantFiled: July 29, 2003Date of Patent: April 14, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
-
Patent number: 7482026Abstract: Chemical formulations and methods for reducing muscle and joint soreness are disclosed. A representative chemical formulation includes compounds such as a selenium-compound, chondroitin sulfate, glucosamine, and/or methylsulfonylmethane. A representative method for reducing muscle and joint soreness includes administering the chemical formulation to a host.Type: GrantFiled: August 31, 2004Date of Patent: January 27, 2009Inventor: Peter L. Revnolds
-
Patent number: 7456158Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: GrantFiled: January 5, 2005Date of Patent: November 25, 2008Assignee: Galderma Laboratories, Inc.Inventors: Robert Ashley, Joseph J. Hlavka
-
Patent number: 7456220Abstract: The invention relates to immunomodulatory compositions and related methods. The immunomodulatory compositions of a formula disclosed herein are useful for the prevention of sepsis and the treatment and prevention of diseases associated with inflammation and/or NOS.Type: GrantFiled: July 7, 2005Date of Patent: November 25, 2008Assignees: Genzyme Corporation, The Brigham and Women's Hospital, Inc.Inventors: Pericles Calias, Robert J. Miller, Andrew B. Onderdonk, Arthur O. Tzianabos
-
Patent number: 7414043Abstract: This invention describes the new 9?-substituted estratrienes of general formula I in which R3, R7, R7?, R13, R16 as well as R17 and R17? have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.Type: GrantFiled: June 11, 2003Date of Patent: August 19, 2008Assignee: Schering AGInventors: Dirk Kosemund, Gerd Mueller, Alexander Hillisch, Karl-Heinrich Fritzemeier, Peter Muhn
-
Patent number: 7371889Abstract: The invention relates to new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.Type: GrantFiled: March 11, 2007Date of Patent: May 13, 2008Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Kalyanam Nagebhuananam, Rajendran Ramanujam, Subbalakshmi Prakash
-
Patent number: 7357925Abstract: PEG-IFN-? conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-?, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-?.Type: GrantFiled: August 28, 2003Date of Patent: April 15, 2008Assignee: Laboratoires SeronosaInventors: Nabil El-Tayar, Michael J. Roberts, Milton Harris, Wayne Sawlivich
-
Patent number: 7335384Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.Type: GrantFiled: March 17, 2006Date of Patent: February 26, 2008Assignee: 4K Nutripharma InternationalInventor: F. Mahnaz Khaled
-
Patent number: 7279158Abstract: The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.Type: GrantFiled: January 5, 2005Date of Patent: October 9, 2007Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, Louis Matis
-
Patent number: 7258857Abstract: The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides for a method for treating inflammation in a subject which comprises administering to the subject an agent in an amount effective to inhibit the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject.Type: GrantFiled: June 1, 2001Date of Patent: August 21, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: David M. Stern, Kevan Herold, Shi Du Yan, Ann Marie Schmidt, Ira Lamster
-
Patent number: 7258853Abstract: Disclosed herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.Type: GrantFiled: September 17, 2002Date of Patent: August 21, 2007Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Wlodzimierz Maslinski
-
Patent number: 7238676Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.Type: GrantFiled: June 15, 2004Date of Patent: July 3, 2007Assignee: Pfizer Inc.Inventors: Simon John Mantell, Sandra Marina Monaghan, Peter Thomas Stephenson
-
Patent number: 7214666Abstract: Provided is a synergistic combination of nutritional supplements classified as Nutraceuticals and further combined with antioxidant vitamins and minerals that, when orally administered to mammals, provides optimal delivery of vital metabolic precursors necessary for the production and repair of articular cartilage. Specifically provided is, a unique combination of chondroitin sulfate sodium, methylsulfonylmethane, glucosamine potassium, glucosamine hydrochloride, glucosamine sulfate sodium, N-acetyl D-Glucosamine, sodium absorbate and chelated manganese proteinate compounded through agitation. The provided compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin.Type: GrantFiled: November 2, 2000Date of Patent: May 8, 2007Inventor: Shawn Paul Madere
-
Patent number: 7205011Abstract: Disclosed herein are mixtures of turmeric extract oils. One mixture of turmeric oils is the hexane soluble fraction obtained by dissolving turmeric powder in hexane to form a hexane mixture, filtering the hexane mixture and evaporating the hexane from the turmeric oil mixture. A more refined turmeric oil combination is the oil left after the turmeric oil mixture is dissolved in hexane, placed on a silica gel/hexane chromatography column, and eluted with hexane into fractions that were then evaporated, thereby leaving the refined turmeric oil combination. Also disclosed are methods for treating inflammation, arthritis and rheumatoid arthritis and a pharmaceutical dosage form of the refined turmeric oil combination.Type: GrantFiled: November 15, 2004Date of Patent: April 17, 2007Assignee: Board of Regents, Acting for and on behalf of, University of ArizonaInventors: Guan Jie Chen, Robert Clark Lantz, Aniko M. Solyom, Barbara N. Timmermann, Shivanand D. Jolad
-
Patent number: 7195759Abstract: An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity.Type: GrantFiled: June 6, 2002Date of Patent: March 27, 2007Assignee: The University of ManitobaInventors: Edris Sabbadini, Eva Nagy, Istvan Berczi
-
Patent number: 7138115Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: September 11, 2003Date of Patent: November 21, 2006Assignee: Genetics Institute, LLCInventors: John P. Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 7135459Abstract: The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed.Type: GrantFiled: December 9, 2002Date of Patent: November 14, 2006Assignee: ZymoGenetics, Inc.Inventors: Theresa A. Deisher, Darrell C. Conklin
-
Patent number: 7109187Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.Type: GrantFiled: February 12, 2001Date of Patent: September 19, 2006Assignee: The Children's Medical Center CorporationInventors: Robert John D'Amato, Moses Judah Folkman
-
Patent number: 7078059Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.Type: GrantFiled: June 26, 2001Date of Patent: July 18, 2006Assignee: Shire Holdings AGInventors: Nigel D. Atherton, Joseph William Totten, Michael David Gaitonde
-
Patent number: 7078438Abstract: The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.Type: GrantFiled: February 4, 2005Date of Patent: July 18, 2006Assignee: Warner-Lambert CompanyInventors: Gordon William Rewcastle, Julie Ann Spicer, Stephen Douglas Barrett, Michael David Kaufman, Jared Bruce John Milbank, Haile Tecle
-
Patent number: 7029703Abstract: A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.Type: GrantFiled: September 9, 2002Date of Patent: April 18, 2006Assignee: Metagenics, Inc.Inventors: Kim C. Krumhar, Holly A. Johnson
-
Patent number: 7011854Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.Type: GrantFiled: February 3, 2003Date of Patent: March 14, 2006Assignee: Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos LdaInventors: Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
-
Patent number: 7001617Abstract: The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. In another aspect of the invention, there is provided a method of preventing excessive release of matrix metalloproteinases from an inflammatory cell in a disease condition in a human or an animal by contacting the cell with a therapeutically effective amount of a noble metal in a crystalline form characterized by atomic disorder, or with a solution derived therefrom to provide a modulatory effect on one or more matrix metalloproteinases, wherein the one or more noble metals is formed with atomic disorder, and preferably in a nanocrystalline form.Type: GrantFiled: May 30, 2002Date of Patent: February 21, 2006Assignee: Nueryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, John Barrymore Wright, Kan Lam
-
Patent number: 6998421Abstract: The present invention comprises a group of related lipid molecules, and methods for their use, that maybe used to treat inflammation and certain inflammation related diseases. The group of related lipid molecules are capable of inhibiting certain enzyme systems including phospholipase A2, and cyclooxygenase-2. The group of related lipid molecules of the invention may be characterized by specific structural characteristics, or by specific biological activity, including inhibition of the previously listed enzymes.Type: GrantFiled: August 26, 2002Date of Patent: February 14, 2006Assignee: Biozone Laboratories, Inc.Inventor: Brian Keller
-
Patent number: 6989156Abstract: Therapeutic treatments using the direct application of selected structures of antimicrobial metals in free-standing powder form, solution form and/or suspension form in therapeutically effective amounts. The selected structures of antimicrobial metals serve as an antimicrobial agent, an anti-inflammatory agent, an immuno modulator agent, an enzyme modulator agent, and/or an anti-tumor agent, for human and/or animal use.Type: GrantFiled: April 23, 2002Date of Patent: January 24, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventor: Scott H. Gillis
-
Patent number: 6979679Abstract: The invention provides compositions useful for the treatment and/or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and/or parenteral use in the treatment and/or prevention of traumaticsynovitis and/or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and/or prevention of inflammatory arthritis, osteoarthritis (OA) and/or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and/or systemic administration comprised of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan (hyaluronic acid) are provided.Type: GrantFiled: October 16, 2003Date of Patent: December 27, 2005Inventor: Frank D. Marcum
-
Patent number: 6962899Abstract: Pharmaceutically acceptable compounds for administering to a subject, comprising the general structure II: wherein R1 is an L-amino acid or salt or ester thereof, or an L-amino acid containing peptide or salt or ester thereof; and wherein the stereochemistry about the carbon-carbon double bond is trans. The invention further relates to pharmaceutical compositions comprising the aforementioned compounds.Type: GrantFiled: December 4, 2002Date of Patent: November 8, 2005Assignees: Georgia Tech Research Corporation, Mercer UniversityInventors: Sheldon W. May, Stanley H. Pollock
-
Patent number: 6949533Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: November 6, 2003Date of Patent: September 27, 2005Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Patent number: 6919374Abstract: It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patient, including those suffering from sickle cell disease and plasma cell dyscrasias. Upon in vivo APM treatment patients experienced a significant lowering of whole blood viscosity. In vitro addition of APM to patients samples having elevated whole blood viscosity resulted in reduced viscosity over time. These in vivo and in vivo results identify APM as a therapeutic agent for molecular diseases which lead to elevated whole blood viscosity. A method by which APM treatment can be monitored is also disclosed.Type: GrantFiled: September 21, 2000Date of Patent: July 19, 2005Assignee: Oklahoma Medical Research FoundationInventor: Carl V. Manion
-
Patent number: 6914051Abstract: A penetrating antibiotic gel for treating pain, inflammation and other pathological conditions affecting musculoskeletal tissues and other soft tissues of the body. The composition includes an antibiotic compound and a mobilizing agent in an amount sufficient to enable the antimicrobial compound to penetrate into the sub-dermal soft tissues. The antimicrobial compound may be a macrolide antibiotic compound such as azithromycin, erythromycin or roxithromycin, for example, and the mobilizing agent may be an organogel compound, such as pluronic lecithin liposomal organogel (PLO). The composition may further include a penetration enhancing adjuvant, such as d-limonene, for example. The composition may be applied topically so as to penetrate into the sub-dermal soft tissues, or may injected so as to be absorbed into the soft tissues locally.Type: GrantFiled: June 28, 2001Date of Patent: July 5, 2005Inventor: David M Allen
-
Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
Patent number: 6911436Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.Type: GrantFiled: June 15, 2001Date of Patent: June 28, 2005Assignee: Dermal Reserach Laboratories, Inc.Inventors: Harold G. Brown, Karen K. Brown -
Patent number: 6896909Abstract: The invention relates to formulations for the topical treatment of disorders with a bioenergetic basis, which contain a suspension obtainable by treating one or more iron ores with aqueous solutions having pH values of between 4 and 8. These formulations will be applied directly to the acupuncture points corresponding to the meridians involved in the conditions to be treated.Type: GrantFiled: May 7, 2002Date of Patent: May 24, 2005Assignee: GeoMedical S.r.l.Inventor: Mauro Fanelli
-
Patent number: 6897206Abstract: The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit inflammation.Type: GrantFiled: July 9, 2002Date of Patent: May 24, 2005Assignee: CombinatoRx, Inc.Inventors: Robyn Sackeyfio, Jason Fong, Nicole Hurst, Palaniyandi Manivasakam, Edward Roydon Jost-Price, Grant Zimmermann, Curtis Keith, Alexis Borisy
-
Patent number: 6894029Abstract: Compositions of substantially homogeneous type II-like collagen from invertebrates belonging to the class Scyphozoa, phylum Coelenterata, i.e., jellyfish, particularly Stomolophus meleagris, and methods for its extraction are provided. Methods for the treatment of arthritis, in particular rheumatoid arthritis, by administering an effective amount of the collagen-containing compositions of the invention so as to induce immune tolerance, are also provided.Type: GrantFiled: November 13, 2001Date of Patent: May 17, 2005Assignee: Auburn UniversityInventor: Yun-Hwa Peggy Hsieh
-
Patent number: 6890569Abstract: A restorative tea system and method of brewing a tea of one part White Willow bark, one part German Chamomile, one part Parsley, one part Nettles leaf, and one part primula veris.Type: GrantFiled: October 18, 2002Date of Patent: May 10, 2005Inventor: Ann M. Tanke
-
Patent number: 6866864Abstract: The present invention provides compositions and method of use for the prevention and treatment of vascular-related disorders such as vascular re-occlusion or restenosis post-coronary intervention with balloon angioplasty or stent procedures and diseases associated with pathological angiogenesis such as cancer, ocular or inflammatory diseases. More specifically, compositions and methods of the present invention involve the combination of the garlic-derived or related compounds and antioxidants.Type: GrantFiled: April 2, 2001Date of Patent: March 15, 2005Inventor: Ahmed Mousa
-
Patent number: 6864251Abstract: Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4.Type: GrantFiled: December 3, 2002Date of Patent: March 8, 2005Assignee: Vela Pharmaceuticals, Inc.Inventors: Robert F. Kucharik, Herbert W. Harris
-
Patent number: 6849058Abstract: Multiple sclerosis and rheumatoid arthritis can be treated effectively using photodynamic therapy. In this protocol, a photoactive compound is administered, allowed to distribute in the effected subject, and the subject is then irradiated to activate the photoactive compound. Alternatively, the blood of a subject to be treated can be subjected to PDT extracorporeally. In the case of rheumatoid arthritis, localized treatment at the joints may also be employed.Type: GrantFiled: May 31, 2000Date of Patent: February 1, 2005Assignee: QLT, Inc.Inventors: Julia G. Levy, Janice North
-
Patent number: 6846841Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Type: GrantFiled: March 28, 2002Date of Patent: January 25, 2005Assignee: Angiotech Pharmaceuticals, Inc.Inventors: William L. Hunter, Lindsay S. Machan, A. Larry Arsenault
-
Patent number: 6844012Abstract: The invention concerns the use of at least a molecule containing selenium, in an amount corresponding to a daily dose of about 2 to 40 mg, even 80 mg of atomic selenium equivalent, on its own or combined with other synergetic molecules for controlling oxidative stress and excessive inflammatory reaction: zinc, vitamin E, vitamin C, iron binder, glutathione precursor, copper and/or copper input binder, for preparing a medicine for treating severe systemic inflammatory response syndrome, in particular any acute infectious condition endangering the patient's life whether of bacterial, parasitic, fungal or viral origin, and any condition corresponding to a severe onset of inflammatory pathology bringing about an exacerbation of cytokine secretion. The invention is applicable in human and veterinary medicine.Type: GrantFiled: August 30, 1999Date of Patent: January 18, 2005Inventors: Xavier Forceville, Dominique Vitoux
-
Patent number: 6841173Abstract: Chemical formulations and methods for reducing muscle and joint soreness are disclosed. A representative chemical formulation includes compounds such as a selenium-compound, chondroitin sulfate, glucosamine, and/or methylsulfonylmethane. A representative method for reducing muscle and joint soreness includes administering the chemical formulation to a host.Type: GrantFiled: March 26, 2002Date of Patent: January 11, 2005Inventor: Peter L. Reynolds
-
Patent number: 6835846Abstract: The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: where n denotes an integer of 1 to 11, and 1 denotes an integer of 1 to 16, the aliphatic compound being an optical isomer of the (2R,3S,2′S) configuration when the 8-position thereof is a double bond, or an optical isomer of the (2S,3R,2′RS) configuration when the 8-position is a single bond; methods for producing the compound or pharmacologically acceptable salts thereof; and uses of the compound in the treatment of cardiovascular diseases (e.g. arteriosclerosis, cardiac diseases), cancer, rheumatism, diabetic retinopathy, and respiratory diseases.Type: GrantFiled: April 11, 2003Date of Patent: December 28, 2004Assignee: Maruha CorporationInventors: Tadakazu Tamai, Masazumi Nishikawa, Kenji Mori
-
Patent number: 6827945Abstract: A nutritional supplement for providing, and for promoting the health of salivary glands and/or supporting normal or healthy swallowing includes ingredients obtainable from turmeric, ginger, and horseradish. The nutritional supplement may also be used to treat symptoms such as symptoms of a common cold, sore throat, congestion, mucositis, laryngitis, mucous membrane inflammation and sialorrhea, as well as inflammation and viral infectin, or to inhibit or exterminate a virus. This nutritional supplement can be orally administered a person. The nutritional supplement may further include optional ingredients such as ingredients obtainable from slippery elm bark powder and green tea, as well as other optional ingredients. This nutritional supplement may further include a pharmaceutically acceptable carrier for oral administration.Type: GrantFiled: April 23, 2003Date of Patent: December 7, 2004Assignee: The Quigley CorporationInventor: Richard A. Rosenbloom
-
Patent number: 6812254Abstract: A composition containing capsaicin together with other ingredients to neutralize the discomfort resulting from the application of capsaicin to the ski enabling treatment of many types of discomforts, including arthritis pain, neuropathy, post surgical scarring, hemorrhoid pain and itching, and pruritis without the discomfort normally associated with the topical application of capsaicin.Type: GrantFiled: March 24, 2000Date of Patent: November 2, 2004Assignee: Medical Merchandising Inc.Inventors: Teresa Leigh Barr, Stephen D. Holt
-
Patent number: 6800300Abstract: Disclosed is a method for treating a mammalian subject suffering from an autoimmune or alloimmune disease by administering to the subject a drug treatment which results in at least partial remission of one or more symptoms of the autoimmune or alloimmune disease, and administering to the subject autologous mammalian blood which has been modified extracorporeally by exposure to at least one stressor selected from an oxidative environment, an electromagnetic emission and a temperature above or below body temperature. The modified mammalian blood is administered to the subject in an amount which is sufficient to maintain the remission of the symptoms of the autoimmune or alloimmune disease.Type: GrantFiled: March 31, 2000Date of Patent: October 5, 2004Assignee: Vasogen Ireland LimitedInventors: Richard G. Miller, Brian Rabinovich
-
Patent number: 6797722Abstract: The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and reumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole. The present invention further discloses a method for inhibiting &ggr;&dgr; T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound.Type: GrantFiled: May 3, 2002Date of Patent: September 28, 2004Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Luca Battistini, Giovanna Borsellino, Rita De Santis, Paolo Carminati
-
Patent number: 6790832Abstract: A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.Type: GrantFiled: April 23, 2002Date of Patent: September 14, 2004Assignee: Aventis Behring GmbHInventors: Jürgen Römisch, Gerhard Dickneite, Peter Gronski, Bernhard Vohwinkel, Harald Stauss, Elaine Gray, Pauline Sxouter, Stephen Poole
-
Patent number: 6790462Abstract: A dietary supplement composition contains phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, and may, optionally, further contain Vitamin D, Vitamin B12, folate and Vitamin B6, provides components that have been linked to bone health.Type: GrantFiled: August 8, 2002Date of Patent: September 14, 2004Assignee: Rhodia Inc.Inventor: Lewis Hendricks
-
Patent number: RE39734Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.Type: GrantFiled: July 13, 2005Date of Patent: July 17, 2007Inventor: Albert Crum